The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results